GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Suven Life Sciences Ltd

Suven Life Sciences Q1 FY27 Consolidated Net Loss at Rs. (12,761.03) Lakhs

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 06 Aug 2026, 12:47 PM IST  ·  BSE ID: 4de4af20-e2b5-429f-bdca-cb78796e32c3
View Original BSE Filing (PDF)
💡
In Simple Terms
Suven Life Sciences reported a significant consolidated net loss for the latest quarter, driven by higher R&D expenses.
🤖 AI Summary
  • Consolidated Net Loss for Q1 FY27 was Rs. (12,761.03) Lakhs, significantly widening year-over-year.
  • Total consolidated income for the quarter ended June 30, 2026, stood at Rs. 1,108.94 Lakhs.
  • Consolidated R&D Expenses for Q1 FY27 increased to Rs. 12,383.10 Lakhs.
  • Rs. 9,331.49 Lakhs received during Q1 FY27 for 1,85,70,133 warrants, with allotment pending.
  • The Board approved Un-Audited Standalone and Consolidated Financial Results on August 6, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from operations
356.58 Lakhs
91.03%
Consolidated Net Profit / (Loss)
(12,761.03) Lakhs
-147.70%
Consolidated R & D Expenses
12,383.10 Lakhs
198.50%
Consolidated Basic EPS
(4.84)
-105.08%
Paid-up equity share capital (Q1 FY27)
2,639.93 Lakhs
21.06%
🏢 How This Affects the Company
📈
Business Impact
The substantial R&D expenditure suggests continued investment in drug discovery and development, aligning with the company's single segment of Research & Development.
💰
Financial Impact
The increased consolidated net loss and R&D expenses indicate significant cash outflows, impacting profitability and potentially requiring careful management of the Rs. 44,813.73 Lakhs balance from the preferential issue.
⚠️
Risk Impact
The high and increasing R&D expenses without corresponding revenue growth present a financial risk, dependent on future success of the research pipeline.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, particularly the increased consolidated net loss per share to Rs. (4.84) Basic EPS from Rs. (2.36) in Q1 FY26.
🔍
Management Signal
The financial results indicate management's continued commitment to significant R&D investment, demonstrated by the Rs. 12,383.10 Lakhs in R&D expenses.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q2 FY27 financial results — check R&D expense trend and revenue generation.
Updates on warrant allotments — monitor conversion of pending 1,85,70,133 warrants.
Company news releases — observe progress in research and development pipeline.
HIGH RISK Significant increase in consolidated net loss and R&D expenses indicates high operational and financial risk.
💡 Investor Takeaway
Suven Life Sciences reported a consolidated Net Loss of Rs. (12,761.03) Lakhs for the quarter ended June 30, 2026, compared to a loss of Rs. (5,151.69) Lakhs in the prior year period. Consolidated R&D Expenses increased to Rs. 12,383.10 Lakhs, contributing to the loss.
⚖️ Strengths & Concerns

✅ Positives

  • Successfully received Rs. 9,331.49 Lakhs during the quarter for 1,85,70,133 warrants, bolstering cash from financing activities.
  • Balance of Rs. 44,813.73 Lakhs from preferential issue proceeds remains available as of June 30, 2026.

⚠️ Concerns

  • Consolidated Net Loss increased to Rs. (12,761.03) Lakhs for Q1 FY27 from Rs. (5,151.69) Lakhs in Q1 FY26.
  • Consolidated R&D Expenses surged to Rs. 12,383.10 Lakhs in Q1 FY27, from Rs. 4,148.84 Lakhs in Q1 FY26.
📅 Company Track Record
Previous filings indicated Suven Life Sciences Q1 FY27 consolidated net loss surged to Rs. (12,761.03) Lakhs. The Board meeting on August 6, 2026, was announced to approve these Q1 FY27 un-audited financial results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Suven Life Sciences' consolidated net loss for Q1 FY27?
Suven Life Sciences reported a consolidated net loss of Rs. (12,761.03) Lakhs for the quarter ended June 30, 2026.
What were Suven Life Sciences' consolidated R&D expenses for the quarter ended June 30, 2026?
Consolidated R&D Expenses for Suven Life Sciences were Rs. 12,383.10 Lakhs for the quarter ended June 30, 2026.
How much income did Suven Life Sciences generate in Q1 FY27?
Suven Life Sciences' total consolidated income for the quarter ended June 30, 2026, was Rs. 1,108.94 Lakhs.
What was the amount received from preferential issue warrants during Q1 FY27?
During Q1 FY27, Suven Life Sciences received Rs. 9,331.49 Lakhs from warrant holders in respect of 1,85,70,133 warrants.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.